32
Page 1 of 32 National Guideline for Good Practices For Pharmaceutical Microbiology Laboratories, 2075 Government of Nepal Ministry of Health Department of Drug Administration National Medicines Laboratory

National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

  • Upload
    others

  • View
    6

  • Download
    0

Embed Size (px)

Citation preview

Page 1: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 1 of 32

National Guideline for Good Practices

For

Pharmaceutical Microbiology Laboratories, 2075

Government of Nepal Ministry of Health

Department of Drug Administration

National Medicines Laboratory

Page 2: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 2 of 32

Table of Contents

1. General requirements for the competence of Pharmaceutical Microbiology Laboratories ............. 3 2. Terms & Definitions ........................................................................................................................ 4

3. Personnel ......................................................................................................................................... 6

4. Environment .................................................................................................................................... 7

5. Microbial Limit test facilities ........................................................................................................ 13

6. Endotoxin test ................................................................................................................................ 14 7. Validation of test methods ............................................................................................................. 14

8. Equipment ..................................................................................................................................... 14

8.1 Maintenance of equipment ............................................................................................................ 14

8.2 Qualification .................................................................................................................................. 14

8.3 Calibration, performance verification and monitoring of use ....................................................... 15

9. Reagents and culture media ........................................................................................................... 17

9.1 Reagents ........................................................................................................................................ 17

9.2 Media ............................................................................................................................................. 17

9.3 Labelling ........................................................................................................................................ 19

10. Reference materials and reference cultures ................................................................................... 19

11. Sampling ........................................................................................................................................ 20 12. Sample handling and identification ............................................................................................... 21

13. Disposal of contaminated waste .................................................................................................... 22

14. Quality assurance of results and quality control of performance .................................................. 22

15. Testing procedures ........................................................................................................................ 22

16. Test reports .................................................................................................................................... 22

References ..................................................................................................................................... 24

Page 3: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 3 of 32

1. General requirements for the competence of Pharmaceutical Microbiology

Laboratories 1.1 Scope

This document is applicable to national and commercial pharmaceutical microbiology

laboratory.

Pharmaceutical microbiology laboratories may be involved in:

sterility testing; detection, isolation, enumeration and identification of microorganisms (bacteria, yeast and

moulds)

testing for bacterial endotoxins in different materials (e.g. starting materials, water), products,

surfaces, garments and the environment; and assay using microorganisms as part of the test

system

These guidelines relate to all microbiology laboratories involved in the above-mentioned

testing activities, whether they are independent or a department or unit of a pharmaceutical

manufacturing facility. These guidelines are based on and supplement the requirements

described in National Guidelines on Good Laboratory Practice for Pharmaceutical Quality

Control Laboratories, 2075.

1.2 Normative References

The following documents are referred to in the text in such a way that some or all of their

content constitutes requirements of this document. For dated references, only the edition cited

applies. For undated references, the latest edition of the referenced document (including any

amendments) applies.

ISO/IEC 17000, Conformity assessment — Vocabulary and general principles

ISO/IEC 17025, General requirements for the competence of testing and

calibration laboratories

Drug Act 2035

Drug Standard Regulation 2043

National GMP Guidelines, 2072

WHO good practices for pharmaceutical microbiology laboratories, WHO

Technical Report Series, No. 961, 2011

WHO good manufacturing practices for pharmaceutical products: main principles

(WHO TRS 986) WHO good practices for pharmaceutical quality control laboratories (WHO TRS

No. 957, 2010) WHO, HANDBOOK of GOOD LABORATORY PRACTICE (GLP);

Page 4: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 4 of 32

2. Terms & Definitions

calibration

The set of operations that establish, under specified conditions, the relationship between values indicated

by an instrument or system for measuring (especially weighing), recording and controlling, or the values

represented by a material measure, and the corresponding known values of a reference standard. Limits for

acceptance of the results of measuring should be established.

certified reference material

Reference material, characterized by a metrologically valid procedure for one or more specified

properties, accompanied by a certificate that provides the value of the specified property, its associated

uncertainty and a statement of metrological traceability.

limit of detection

The lowest number of microorganisms that can be detected but in numbers that cannot be estimated

accurately.

precision

The degree of agreement among individual results.

quantitation limit (limit of quantitation)

Applied to quantitative microbiological tests. The lowest number of microorganisms within a defined

variability that may be counted under the experimental conditions of the method under evaluation.

reference cultures

Collective term for reference strain and reference stocks.

reference material

Material sufficiently homogeneous and stable with respect to one or more specified properties, which has

been established to be fit for its intended use in a measurement process.

reference method

A method which has been validated as being fit for purpose, with which an alternative method may be

compared.

reference stocks

A set of separate identical cultures obtained by a single subculture from the reference strain.

reference strains

Microorganisms defined at least to the genus and species level, catalogued and described according to its

characteristics and preferably stating its origin. Normally obtained from a recognized national or

international collection.

Page 5: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 5 of 32

repeatability

Closeness of the agreement between the results of successive measurements of the same measure and

under the same conditions of measurement (adapted from ISO).

reproducibility

Reproducibility expresses precision between laboratories.

robustness (or ruggedness)

The ability of the procedure to provide analytical results of acceptable accuracy and precision under a

variety of conditions.

sensitivity

The fraction of the total number of positive cultures or colonies correctly assigned in the presumptive

inspection .

specificity (selectivity)

The ability of the method to detect the required range of microorganisms that might be present in the test

sample.

validation

Action of proving, in accordance with the principles of good practice quality guidelines and regulations

(GxP), that any procedure, process, equipment (including the software or hardware used), material,

activity or system actually and consistently leads to the expected results.

verification

The application of methods, procedures, tests and other evaluations, in addition to monitoring, to

determine compliance with GxP principles.

working culture

A primary subculture from a reference stock.

Page 6: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 6 of 32

3. Personnel

3.1 Microbiological testing should be performed and supervised by an experienced person,

qualified in B. Pharmacy or B.Sc/MSc in microbiology or equivalent. Staff should have

basic training in microbiology and relevant practical experience before being allowed to

perform work covered by the scope of testing.

3.2 Current job descriptions for all personnel involved in tests and/ or calibrations, validations

and verifications should be maintained.

The laboratory should also maintain records of all technical personnel, describing their

qualifications, training and experience.

3.3 If the laboratory includes opinions and interpretations of test results in reports, this should

be done by authorized personnel with suitable experience and relevant knowledge of the

specific application including, for example, regulatory and technological requirements and

acceptability criteria.

3.4 The laboratory management should ensure that all personnel have received adequate

training for the competent performance of tests and operation of equipment. This should

include training in basic techniques, e.g. plate pouring, counting of colonies, aseptic

technique, media preparation, serial dilutions, and basic techniques in identification, with

acceptability determined using objective criteria where relevant. Personnel may only

perform tests on samples either if they are recognized as competent to do so, or if they do

so under adequate supervision. Competence should be monitored continuously with

provision for retraining where necessary.

Where a method or technique is not in regular use, the competency of the personnel to perform the

test should be verified before testing is undertaken. In some cases it is acceptable to relate

competence to a general technique or instrument being used rather than to particular methods.

3.5 Personnel should be trained in necessary procedures for containment of microorganisms

within the laboratory facility.

3.6 Personnel should be trained in safe handling of microorganisms.

3.7 Only the minimum number of personnel required should be present in clean areas; this is

particularly important during aseptic processes. As far as possible, inspections and controls

should be conducted from outside such areas.

3.8 Staff who have been engaged in the processing of animal-tissue materials or of cultures of

microorganisms other than those used in the current manufacturing process should not

enter sterile-product areas unless rigorous and clearly defined decontamination procedures

have been followed.

Page 7: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 7 of 32

4. Environment

4.1 Premises

4.1.1 Microbiology laboratories and certain support equipment (e.g. autoclaves and glassware)

should be dedicated and separated from other areas, especially from production areas.

4.1.2 Microbiology laboratories should be designed to suit the operations to be carried out in

them. There should be sufficient space for all activities to avoid mix ups, contamination

and cross-contamination. There should be adequate suitable space for samples, reference

organisms, media (if necessary, with cooling), testing and records. Due to the nature of

some materials (e.g. sterile media versus reference organisms or incubated cultures),

separate storage locations may be necessary.

4.1.3 Laboratories should be appropriately designed and should take into account the

suitability of construction materials to enable appropriate cleaning, disinfection and

minimize the risks of contamination.

4.1.4 There should be separate air supply to laboratories and production areas. Separate air-

handling units and other provisions, including temperature and humidity controls where

required, should be in place for microbiological laboratories. The air supplied to the

laboratory should be of appropriate quality and should not be a source of contamination.

4.1.5 Access to the microbiological laboratory should be restricted to authorized personnel.

Personnel should be made aware of:

— the appropriate entry and exit procedures including gowning;

— the intended use of a particular area;

— the restrictions imposed on working within such areas;

— the reasons for imposing such restrictions; and

— the appropriate containment levels.

4.1.6 Laboratory activities, such as sample preparation, media and equipment preparation and

enumeration of microorganisms, should be segregated., false-positive results and false-

negative results. Sterility testing should always be performed in a dedicated area.

Culture handling and microbial limit test area should be segregated.

4.1.7 Consideration should be given to designing appropriate classified areas for the

operations to be performed within the microbiology laboratory. The classification should

be based on the criticality of the product and the operation being carried out in the area.

Sterility testing should be performed under the same class as used for sterile/aseptic

manufacturing operations. Zonal classifications should be as follows:

Page 8: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 8 of 32

Zone Grade Class ISO

Sample receipt Unclassified

Media Preparation D 100000 7

Autoclave loading D 100000 7

Decontamination Unclassified ……. ……

Autoclave unloading, inside the Grade B 100 5

sterility testing area

Autoclave unloading, inside the area Grade D 100000 7

other than the sterility testing area

Microbial Limit Test (MLT) Grade A 100 5

Background to MLT area At least Grade C At least 10000 7

Microbial Limit Test (MLT) Grade A 100 5

Sterility Testing Grade A 100 5

Background to sterility testing area Graded B 100 5

Enumeration Grade D 100000 7

Incubator Grade D 100000 7

Endotoxin test Grade A 100 5

Background to endotoxin test area At least Grade C At least 10000 7

4.1.8 In general, laboratory equipment should not routinely be moved between areas of

different cleanliness class, to avoid accidental cross contamination. Laboratory

equipment used in the microbiology laboratory should not be used outside the

microbiology area, unless there are specific precautions in place to prevent cross-

contamination.

4.2 Environmental monitoring in the laboratory

Where necessary and appropriate an environmental monitoring programme should be in

place which covers environmental microbiological monitoring and temperature and

pressure differentials. Alert and action limits should be defined. Trending of

environmental monitoring results should be carried out.

Page 9: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 9 of 32

4.2.1 Environmental microbiological monitoring should reflect the facility used (room or

isolator) and include a combination of air and surface sampling methods appropriate to

the facility, such as:

— active air sampling;

— settle (exposure) plates;

— surface contact

— replicate organism detection and counting (RODAC) plates, swabs or

flexible films;

— operators’ glove prints.

Microbial environmental monitoring of the sterility test zone should be performed during

every work session under operational (dynamic) conditions and for the microbial limit test

and endotoxin testing area, the frequency should be defined to ensure the bioburden is within

specified limit. There should be written specifications, including appropriate alert and action

limits for microbial contamination. Limits for microbiological environmental monitoring are

as per National GMP Code, 2072.

Limit for microbiogical environmental monitoring:

Grade Air Sample Settle plates Contact plates Glove points

Cfu/m3

90mm diam. 55mm diam. forefingers

Cfu/4hrs cfu/plate cfu/glove*

A <1 <10 <1 <1

B 10 5 5 5

C 100 50 25 ------

D 200 100 50 ------.

*optional for other tests except sterility testing

4.2.2 Cleaning, disinfection and hygiene

There should be a documented cleaning and disinfection program. Results of

environmental monitoring should be considered where relevant. There should be a

procedure for dealing with spillages. Adequate hand-washing and hand-disinfection

facilities should be available.

4.2.3 Sterility test facilities

4.2.3.1 Sterility test facilities have specific environmental requirements to ensure the integrity

of tests carried out. Sterility testing should be carried out and specifies requirements

Page 10: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 10 of 32

for sterility testing. This section details the clean-room requirements for a sterility test

facility.

4.2.3.2 Sterility testing should be performed under aseptic conditions, which should be

equivalent to air quality standards required for the aseptic manufacture of

pharmaceutical products. The premises, services and equipment should be subject to

the appropriate qualification process.

4.2.3.3 The sterility testing should be carried out within a Grade A unidirectional airflow

protected zone or a biosafety cabinet (if warranted), which should be located within a

clean room with a Grade B background. Alternatively, the testing can be carried out

within a barrier isolator. Care should be taken with the design of the facility layout and

room airflow patterns, to ensure that the unidirectional airflow patterns are not

disrupted.

4.2.3.4 The clean-room classification and air-handling equipment of the sterility test facilities

should be requalified at least annually by a competent person or contractor. The

environment should comply with the non-viable and viable limits, and verification of

high efficiency particulate air (HEPA) filter integrity and room airflows should be

performed. Mapping locations for sample points for routine monitoring should be

documented, as well as exposure duration, and frequency of all types of microbiological

environmental monitoring should be specified in written procedures.

4.2.3.5 Air supplied to Grade A and B zones should be via terminal HEPA filters.

4.2.3.6 Appropriate airflow alarms and pressure differentials and indication instruments should

be provided (GMP: Heating, ventilation and air-conditioning systems for non- sterile

pharmaceutical dosage forms and GMP for sterile pharmaceutical products.

4.2.3.7 Room pressure readings should be taken and recorded from externally mounted gauges

unless a validated continuous monitoring system is installed. As a minimum, readings

should be taken prior to entry of the operator to the test suite. Pressure gauges should be

labeled to indicate the area served and the acceptable specification.

4.2.3.8 Entry to the clean room should be via a system of airlocks and a change room where

operators are required to don suitable clean-room garments. The final change room

should be under ―at rest‖ conditions of the same grade as the room it serves. Change

rooms should be of adequate size for ease of changing. There should be clear

demarcation of the different zones.

4.2.3.9 Outdoor clothing should not be brought into changing rooms leading to Grade B and C

rooms. For every worker in a Grade A/B area, clean sterile (sterilized or adequately

sanitized) protective garments should be provided at each work session. Gloves should

be regularly disinfected during operations. Masks and gloves should be changed at

Page 11: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 11 of 32

least every working session. Operators working in Grade A and B areas should

wear sanitized goggles.

4.2.3.10 Wrist-watches, cosmetics and jewellery should not be worn in clean areas.

4.2.3.11 The clothing required for each grade is as follows:

• Grade D. The hair and, where relevant, beard and moustache should be covered.

Protective clothing and appropriate shoes or overshoes should be worn. Appropriate

measures should be taken to avoid any contamination from outside the clean area.

• Grade C. The hair and, where relevant, beard and moustache should be covered. A

one-piece jumpsuit, gathered at the wrists and with a high neck, and appropriate

shoes or overshoes should be worn. The clothing should shed virtually no fibres or

particulate matter.

• Grades A and B. Entry of personnel into Grade A areas should be minimized.

Headgear should totally enclose the hair and, where relevant, beard and moustache. A

one-piece jumpsuit, gathered at the wrists and with a high neck, should be worn. The

headgear should be tucked into the neck of the suit. A facemask should be worn to

prevent the shedding of droplets. Sterilized, non-powdered gloves of appropriate

material and sterilized or disinfected footwear should be worn. Trouser-bottoms

should be tucked inside the footwear and garment sleeves into the gloves. The

protective clothing should shed virtually no fibres or particulate matter and should

retain particles shed by the body.

4.2.3.12 Clothing used in clean areas should be laundered or cleaned in such a way that it does

not gather additional particulate contaminants that can later be shed. Separate laundry

facilities for such clothing are desirable. If fibres are damaged by inappropriate cleaning

or sterilization, there may be an increased risk of shedding particles. Washing and

sterilization operations should follow standard operating procedures. Operators should

be trained and certified in gowning procedures with training records maintained.

4.2.3.13 All premises should as far as possible be designed to avoid the unnecessary entry of

supervisory or control personnel. Grade A and B areas should be designed so that all

operations can be observed from outside.

4.2.3.14 In clean areas all exposed surfaces should be smooth, impervious and unbroken to

minimize the shedding or accumulation of particles or microorganisms and to permit the

repeated application of cleaning agents and disinfectants, where used.

4.2.3.15 To reduce the accumulation of dust and to facilitate cleaning, there should be no

uncleanable recesses and a minimum of projecting ledges, shelves, cupboards and

equipment. Doors should be carefully designed to avoid uncleanable recesses; sliding

doors may be undesirable for this reason. Swing doors should open to the high-

Page 12: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 12 of 32

pressure side and be provided with self-closers. Exceptions are permitted based on

egress and site environmental, health and safety containment requirements.

4.2.3.16 False ceilings should be sealed to prevent contamination from the void space above

them.

4.2.3.17 Pipes and ducts and other utilities should be installed so that they do not create

recesses, unsealed openings and surfaces that are difficult to clean. Sanitary pipes and

fittings should be used and threaded pipe connections should be avoided.

4.2.3.18 Sinks and drains should be avoided wherever possible and should be excluded from

Grade A and B areas where aseptic operations are carried out. Where installed they

should be designed, located and maintained so as to minimize the risks of microbial

contamination; they should be fitted with effective, easily cleanable traps and with air

breaks to prevent backflow. Any floor channels should be open and easily cleanable

and be connected to drains outside the area in a manner that prevents the ingress of

microbial contaminants.

4.2.3.19 Changing rooms should be designed as airlocks and used to provide physical separation

of the different stages of changing and so minimize microbial and particulate

contamination of protective clothing. They should be flushed effectively with filtered

air. The final stage of the changing room should, in the at-rest state, be the same grade

as the area into which it leads. The use of separate changing rooms for entering and

leaving clean areas is sometimes desirable. In general hand-washing facilities should

be provided only in the first stage of the changing rooms. There should not be a change

of more than one grade between airlocks or passages and changing rooms, i.e. a Grade

D passage can lead to a Grade C airlock, which leads to a Grade B changing room,

which leads to a Grade B clean room. Changing rooms should be of a sufficient size to

allow for ease of changing. Changing rooms should be equipped with mirrors so that

personnel can confirm the correct fit of garments before leaving the changing room.

4.2.3.20 Airlock doors should not be opened simultaneously. An interlocking system and a

visual and/or audible warning system should be operated to prevent the opening of

more than one door at a time.

4.2.3.21 A filtered air supply should be used to maintain a positive pressure and an airflow

relative to surrounding areas of a lower grade under all operational conditions; it

should flush the area effectively. Adjacent rooms of different grades should have a

pressure differential of approximately 10–15 Pascals (guidance value). Particular

attention should be paid to the protection of the zone of greatest risk, i.e. the immediate

environment to which the product and the cleaned components in contact with it are

exposed. The recommendations regarding air supplies and pressure differentials may

need to be modified where it becomes necessary to contain certain materials, e.g.

Page 13: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 13 of 32

pathogenic, highly toxic, radioactive or live viral or bacterial materials or products.

The decontamination of the facilities and the treatment of air leaving a clean area may

be necessary for some operations.

4.2.3.22 It should be demonstrated that airflow patterns do not present a contamination risk; for

example, care should be taken to ensure that particles from a particle-generating

person, operation or machine are not conveyed to a zone of higher product risk.

4.2.3.23 A warning system should be operated to indicate failure in the air supply. Indicators of

pressure differentials should be fitted between areas where this difference is important,

and the pressure differentials should be regularly recorded and failure alarmed.

4.2.3.24 Consideration should be given to restricting unnecessary access to critical filling areas,

e.g. Grade A filling zones, by means of a physical barrier.

5. Microbial Limit test facilities:

5.1 Microbial limit test should be performed in dedicated zone as defined in section 4.1.7.

5.2 Microbial limit test should be performed under Grade A unidirectional airflow protected

zone surrounded by at least Grade C background.

5.3 The air quality should be monitored regularly and requalified at least annually by a

competent person or contractor.

5.4 Entry to the microbial limit test facilities should be via a system of airlock/s and a change

room where operators are required to don suitable clean room garments.

5.5 There should be separate facilities for personnel and material entry.

6. Endotoxin test:

6.1 Endotoxin test should be performed in zone as defined in section 4.1.7.

6.2 Endotoxin test should be performed under Grade A unidirectional airflow protected

zone surrounded by at least Grade C background.

6.2.1 The air quality should be monitored regularly and requalified at least annually by a

competent person or contractor.

6.2.2 Entry to the endotoxin facilities should be via a system of airlock/s and a change room

where operators are required to don suitable clean room garments.

6.2.3 There should be separate facilities for personnel and material entry.

6.2.4 Other requirements for clean room is as per sterility test facilities (for eg, piping,

ducting false ceiling etc.)

Page 14: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 14 of 32

7. Validation of test methods

7.1 Standard (pharmacopoeial) test methods are considered to be validated.

However, the specific test method to be used by a specific laboratory for

testing of a specific product needs to be shown to be suitable for use in

recovering bacteria, yeast and mould in the presence of the specific product.

The laboratory should demonstrate that the performance criteria of the standard

test method can be met by the laboratory before introducing the test for routine

purposes (method verification) and that the specific test method for the specific

product is suitable (test method suitability including positive and negative

controls).

7.2 Test methods not based on compendial or other recognized references should

be validated before use. The validation should comprise, where appropriate,

determining accuracy, precision, specificity, limit of detection, limit of

quantitation, linearity and robustness. Potentially inhibitory effects from the

sample should be taken into account when testing different types of sample.

The results should be evaluated with appropriate statistical methods, e.g. as

described in the national, regional or international pharmacopoeias.

8. Equipment

Each item of equipment, instrument or other device used for testing, verification and

calibration should be uniquely identified. As part of its quality system, a laboratory

should have a documented programme for the qualification, calibration, performance

verification, maintenance and a system for monitoring the use of its equipment.

8.1 Maintenance of equipment

Maintenance of essential equipment should be carried out at predetermined intervals in

accordance with a documented procedure. Detailed records should be kept.

8.2 Qualification

For qualification of equipment see sections 4.8 and 5.3 in National Guidelines for Good

Laboratory Practices for Pharmaceutical Quality Control Laboratories.

Page 15: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 15 of 32

8.3 Calibration, performance verification and monitoring of use

8.3.1 The date of calibration and servicing and the date when recalibration is due should be

clearly indicated on a label attached to the instrument.

8.3.2 The frequency of calibration and performance verification will be determined by

documented experience and will be based on need, type and previous performance of the

equipment. Intervals between calibration and verification should be shorter than the time the

equipment has been found to take to drift outside acceptable limits. The performance of the

equipment should conform to predefined acceptance criteria.

8.3.3 Temperature measurement devices

Where temperature has a direct effect on the result of an analysis or is critical for the

correct performance of equipment, temperature measuring devices should be of

appropriate quality to achieve the accuracy required (e.g. liquid-in-glass

thermometers, thermocouples and platinum resistance thermometers (PRTs) used in

incubators and autoclaves).

8.3.3.1 Calibration of devices should be traceable to national or international standards for temperature.

8.3.4 Incubators, water-baths and ovens

The stability of temperature, uniformity of temperature distribution and time required to

achieve equilibrium conditions in incubators, water-baths, ovens and temperature-controlled

rooms should be established initially and documented, in particular with respect to typical

uses (for example, position, space between, and height of, stacks of Petri dishes). The

constancy of the characteristics recorded during initial validation of the equipment should be

checked and recorded after each significant repair or modification. The operating temperature

of this type of equipment should be monitored and records retained. The use of the equipment

should be considered when determining what temperature controls are required.

8.3.5 Autoclaves, including media preparators 8.3.5.1 Autoclaves should be capable of meeting specified time and temperature tolerances;

monitoring pressure alone is not acceptable. Sensors used for controlling or monitoring

operating cycles require calibration and the performance of timers should be verified.

8.3.5.2 Initial validation should include performance studies (spatial temperature distribution

surveys) for each operating cycle and each load configuration used in practice. This process

must be repeated after any significant repair or modification (e.g. replacement of

thermoregulatory probe or programmer, change to loading arrangements or operating cycle)

Page 16: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 16 of 32

or where indicated by the results of quality control checks on media or risk assessment.

Sufficient temperature sensors should be positioned within the load (e.g. in containers filled

with liquid/medium) to enable location differences to be demonstrated.

8.3.5.3 Clear operating instructions should be provided based on the heating profiles determined for

typical uses during validation/revalidation. Acceptance/rejection criteria should be

established and records of autoclave operations, including temperature and time, maintained

for every cycle.

8.3.5.4 Monitoring may be achieved by one of the following:

— using a thermocouple and recorder to produce a chart or printout;

— direct observation and recording of maximum temperature achieved and time at that

temperature.

In addition to directly monitoring the temperature of an autoclave, the effectiveness of its

operation during each cycle may be checked by the use of chemical or biological indicators

for sterilization and decontamination purposes. Autoclave tape or indicator strips should be

used only to show that a load has been processed, not to demonstrate completion of an

acceptable cycle. Laboratories should have a separate autoclave for decontamination.

8.3.6 Weights and balances

Weights and balances shall be calibrated traceably at regular intervals (according to their

intended use) using appropriate standard weights traceable to certified standard weights. 8.3.7 Volumetric equipment

8.3.7.1 Microbiology laboratories should carry out initial verification of volumetric equipment

(automatic dispensers, dispenser/diluters, mechanical hand pipettes and disposable pipettes)

and then make regular checks, as appropriate, to ensure that the equipment is performing

within the required specification. Initial verification should not be necessary for glassware

which has been certified to a specific tolerance. Equipment should be checked for the

accuracy of the delivered volume against the set volume (for several different settings in the

case of variable volume instruments) and the precision of the repeat deliveries should be

measured.

8.3.7.2 For ―single-use‖ disposable volumetric equipment, laboratories should obtain supplies from

companies with a recognized and relevant quality system. After initial validation of the

suitability of the equipment, it is recommended that random checks on accuracy are carried

out. If the supplier does not have a recognized quality system, laboratories should check

each batch of equipment for suitability.

Page 17: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 17 of 32

8.3.8 Other equipment

Conductivity meters, oxygen meters, pH meters and other similar instruments should be

verified regularly or before each use. The buffers used for verification purposes should be

stored in appropriate conditions and should be marked with an expiry date.

Where humidity is important to the outcome of the test, hygrometers should be calibrated,

the calibration being traceable to national or international standards. Timers, including the

autoclave timer, should be verified using a calibrated timer or national time signal. When

centrifuges are used in test procedures, an assessment of the rotations per minute (RPM)

should be made. Where it is critical, the centrifuge should be calibrated.

9. Reagents and culture media

Laboratories should ensure that the quality of reagents and media used is appropriate for the

test concerned. 9.1 Reagents

Laboratories should verify the suitability of prepared reagents critical for the test, initially

and during its shelf-life.

9.2 Media

9.2.1 Media may be prepared in-house or purchased either partially or fully prepared. Vendors of

purchased media should be approved and qualified. The qualified vendor may certify some of

the quality parameters listed subsequently. Growth promotion and, if appropriate, other

suitable performance tests (see section 9.2.3) should be done on all media on every batch and

on every shipment. Where the supplier of fully prepared media is qualified and provides

growth promotion certification per batch of media and transportation conditions have been

qualified, the user may rely on the manufacturer’s certificate with periodic verification of his

or her results.

9.2.2 The suitable performance of culture media, diluents and other suspension fluids should be

checked, where relevant, with regard to:

— recovery or survival maintenance of target organisms. Recovery of 50–

200% (after inoculation of not more than 100 colony-forming units (CFU or

cfu) should be demonstrated;

—inhibition or suppression of non-target organisms;

—biochemical (differential and diagnostic) properties; and

— other appropriate properties (e.g. pH, volume and sterility).

Quantitative procedures for evaluation of recovery or survival are preferred.

Page 18: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 18 of 32

9.2.3 Raw materials (both commercial dehydrated formulations and individual constituents) and

media should be stored under appropriate conditions recommended by the manufacturer, e.g.

cool, dry and dark. All containers, especially those for dehydrated media, should be sealed

tightly. Dehydrated media that are caked or cracked or show a color change should not be

used.

9.2.4 Water of a suitable microbiological quality should be used for preparation unless the test

method specifies otherwise. The limit for microbial limit and frequency of testing should be

defined.

9.2.5 Media containing antimetabolites or inhibitors should be prepared using dedicated glassware,

as carry-over of these agents into other media could inhibit the growth and detection of

microorganisms present in the sample under test. If dedicated glassware is not used, washing

procedures for glassware should be validated.

9.2.6 Repartition of media after sterilization should be performed under unidirectional airflow

(UDAF) to minimize potential for environmental contamination. This should be considered a

minimum requirement for media to be used in relation to sterile product testing. This includes

the cooling of media, as container lids will need to be removed during cooling to prevent

build-up of condensation.

9.2.7 Plated media which is to be irradiated may require the addition of an antioxidant and free

radical scavenger to provide protection from the effects of the irradiation process. The

irradiated media should be validated by performing quantitative growth promotion testing on

both irradiated and non-irradiated media.

9.2.8 Shelf-life of prepared media under defined storage conditions shall be determined and

verified.

9.2.9 Batches of media should be identifiable and their conformance with quality specifications

documented. For purchased media the user laboratory should ensure that it will be notified by

the manufacturer of any changes to the quality specification.

9.2.10 Media should be prepared in accordance with any manufacturer’s instructions, taking into

careful account specifications such as time and temperature for sterilization.

Page 19: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 19 of 32

9.2.11 Microwave devices should not be used for the melting of media due to the inconsistent

distribution of the heating process.

9.3 Labelling

9.3.1 Laboratories should ensure that all reagents (including stock solutions), media, diluents and

other suspending fluids are adequately labelled to indicate, as appropriate, identity,

concentration, storage conditions, preparation date, validated expiry date and/or

recommended storage periods. The person responsible for preparation should be identifiable

from records.

9.3.2 Organism resuscitation

— Organism resuscitation is required where test methodologies may

— injurious effects of processing, e.g. heat;

— antimicrobial agents;

— preservatives;

— extremes of osmotic pressure; and

— extremes of pH.

9.3.3 Organism resuscitation may be achieved by:

— exposure to a liquid media like a simple salt solution at room temperature for 2 hours;

— exposure to a solid repair medium for 4–6 hours.

10. Reference materials and reference cultures

10.1 International standards and pharmacopoeial reference substances

10.1.1 Reference materials and certified reference materials are generally used in a microbiological

laboratory to qualify, verify and calibrate equipment. Whenever possible these reference

materials should be used in appropriate matrices. International standards and

pharmacopoeial reference substances are employed, for example, to:

—determine potency or content;

—validate methods;

—enable comparison of methods;

—perform positive controls; and

—perform growth promotion tests.

If possible reference materials should be used in appropriate matrices.

Page 20: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 20 of 32

10.2 Reference cultures

10.2.1 Reference cultures are required for establishing acceptable performance of media

(including test kits), for validating methods, for verifying the suitability of test

methods and for assessing or evaluating ongoing performance. Traceability is

necessary, for example, when establishing media performance for test kit and

method validations. To demonstrate traceability, laboratories must use reference

strains of microorganisms obtained directly from a recognized national or

international collection, where these exist. Alternatively, commercial derivatives for

which all relevant properties have been shown by the laboratory to be equivalent at

the point of use may be used.

10.2.2 Reference strains may be subcultured once to provide reference stocks. Purity and

biochemical checks should be made in parallel as appropriate. It is recommended to

store reference stocks in aliquots either deep-frozen/ lyophilized or in 2-8degreec,

provided that the adequate validation has been done ensure that the property has not

been altered with reference to reference strains with documentary evidence.

Working cultures for routine use should be primary subcultures from the reference

stock. If reference stocks have been thawed, they must not be refrozen and reused.

10.2.3 Working stocks should not be subcultured. Usually not more than five generations

(or passages) from the original reference strain can be subcultured if defined by a

standard method or laboratories can provide documentary evidence that there has

been no change in any relevant property. Commercial derivatives of reference

strains may only be used as working cultures.

11. Sampling

For general principles reference is made to National guidelines for Good Laboratory Practice

for Pharmaceutical Laboratory Practices, 2075.

11.1 Where testing laboratories are responsible for primary sampling to obtain test

items, it is strongly recommended that this sampling be covered by a quality

assurance system and it should be subject to regular audits.

11.2 Any disinfection processes used in obtaining the sample (e.g. disinfection of

sample points) should not compromise the microbial level within the sample.

Page 21: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 21 of 32

11.3 Transport and storage of samples should be under conditions that maintain the

integrity of the sample (e.g. chilled or frozen where appropriate). Testing of the

samples should be performed as soon as possible after sampling.

11.4 For samples where a growth in the microbial population during transport and

storage is possible it should be demonstrated that the storage conditions, time and

temperature, will not affect the accuracy of the testing result. The storage

conditions should be monitored and records kept. The responsibility for transport,

storage between sampling and arrival at the testing laboratory should be clearly

documented.

11.5 Sampling should only be performed by trained personnel. It should be carried out

aseptically using sterile equipment. Appropriate precautions should be taken to

ensure that sample integrity is maintained through the use of sterile sealed

containers for the collection of samples where appropriate. It may be necessary to

monitor environmental conditions, for example, air contamination and

temperature, at the sampling site. Time of sampling should be recorded, if

appropriate.

12. Sample handling and identification

12.1 The laboratory should have procedures that cover the delivery and receipt of samples and

sample identification. If there is insufficient sample or the sample is in poor condition due

to physical deterioration, incorrect temperature, torn packaging or deficient labelling, the

laboratory should consult with the client before deciding whether to test or refuse the

sample.

12.2 The laboratory should record all relevant information, e.g.

— date and, where relevant, the time of receipt;

— condition of the sample on receipt and, when necessary, temperature; and

— characteristics of the sampling operation (including sampling date and sampling

conditions).

12.3 Samples awaiting testing should be stored under suitable conditions to minimize changes

to any microbial population present. Storage conditions should be validated, defined and

recorded.

12.4 The packaging and labels of samples may be highly contaminated and should be handled

and stored with care so as to avoid any spread of contamination. Disinfection processes

Page 22: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 22 of 32

applied to the outer container should not affect the integrity of the sample. It should be

noted that alcohol is not sporicidal.

12.5 Subsampling by the laboratory immediately prior to testing may be required as part of the

test method. It may be appropriate that it is performed according to national or

international standards, where they exist, or by validated in-house methods. Subsampling

procedures should be designed to collect a representative sample.

12.6 There should be a written procedure for the retention and disposal of samples. If sample

integrity can be maintained it may be appropriate that samples are stored until the test

results are obtained, or longer if required. Laboratory sample portions that are known to

be contaminated should be decontaminated prior to being discarded.

13. Disposal of contaminated waste

The procedures for the disposal of contaminated materials should be designed to

minimize the possibility of contaminating the test environment or materials. It is a

matter of good laboratory management and should conform to national/

international environmental or health and safety regulations.

14. Quality assurance of results and quality control of performance

14.1 Internal quality control

The laboratory should have a system of internal quality assurance or quality control (e.g.

handling deviations, use of spiked samples, replicate testing and participation in

proficiency testing, where appropriate) to ensure the consistency of results from day to

day and their conformity with defined criteria.

15. Testing procedures

15.1 Testing should normally be performed according to procedures described in the

national, regional and international pharmacopoeias or pharmacopoeia recognized by

Drug Standard Regulation, 2043.

15.2 Alternative testing procedures may be used if they are appropriately validated and

equivalence to official methods has been demonstrated.

16. Test reports

16.1 If the result of the enumeration is negative, it should be reported as ―not detected for a

defined unit‖ or ―less than the detection limit for a defined unit‖. The result should not

be given as ―zero for a defined unit‖ unless it is a regulatory requirement. Qualitative

test results should be reported as ―detected/not detected in a defined quantity or

Page 23: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 23 of 32

volume‖. They may also be expressed as ―less than a specified number of organisms

for a defined unit‖ where the specified number of organisms exceeds the detection

limit of the method and this has been agreed with the client. In the raw data the result

should not be given as zero for a defined unit unless it is a regulatory requirement. A

reported value of ―0‖ may be used for data entry and calculations or trend analysis in

electronic databases

16.2 Where an estimate of the uncertainty of the test result is expressed on the test report,

any limitations (particularly if the estimate does not include the component

contributed by the distribution of microorganisms within the sample) have to be made

clear to the client.

Page 24: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 24 of 32

References

1. National Guidelines for Good Laboratory Practices for Pharmaceutical Quality

Control Laboratories, 2075

2. National GMP Code, 2072

3. Drug Standard Regulation, 2043

4. Good Practices for pharmaceutical quality control laboratories. In: WHO Expert

Committee on Specifications for Pharmaceutical Preparations. Forty fourth

report. Geneva, World Health Organization. WHO Technical Report Series, No.

957, 2010, Annex 1.

5. General guidelines for the establishment, maintenance and distribution of chemical

reference substances. Revision. In: WHO Expert Committee on Specifications for

Pharmaceutical Preparations. Forty-first report. Geneva, World Health

Organization. WHO Technical Report Series, No. 943, 2007, Annex 3.

6. The International Pharmacopoeia, Fourth Edition. Geneva, World Health

Organization, 2006. Also available on CD-ROM.

7. The International Pharmacopoeia, Fourth Edition, First Supplement. Geneva,

World Health Organization, 2008. Also available on CD-ROM.

8. ISO/IEC 17025 (2017) General requirements for the competence of testing and

calibration laboratories.

9. ISO 11133-1 (2000) Microbiology of food and animal feeding stuffs — Guidelines

on preparation and production of culture media — Part 1: General guidelines on

quality assurance for the preparation of culture media in the laboratory.

10. ISO 13843 (2000) Water quality — Guidance on validation of microbiological methods.

11. WHO good manufacturing practices: main principles for pharmaceutical products.

In: Quality assurance of pharmaceuticals. A compendium of guidelines and related

materials. Volume 2, 2nd updated edition. Good manufacturing practices (GMP)

and inspection. Geneva, World Health Organization, 2007, and subsequent updates,

including WHO GMP for sterile pharmaceutical products. In: WHO Expert

Committee on Specifications for Pharmaceutical Preparations. Forty-fifth report.

Geneva, World Health Organization. WHO Technical Report Series, No. 961,

Annex 6, 2011; and GMP: Heating, ventilation and air-conditioning systems for

non-sterile pharmaceutical dosage forms. In: WHO Expert Committee on

Specifications for Pharmaceutical Preparations. Forty-fifth report.

Page 25: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 25 of 32

NML-GLP-F-1

Government of Nepal

Ministry of Health

Department of Drug Administration

National Medicines Laboratory

ATTENDANCE SHEET (OPENING / CLOSING MEETING) Industry/Laboratory: Location:

Date : Opening Meeting Time: Closing Meeting Time:

Type of Visit: Assessment / 1st

Surveillance / Re-Assessment / Supplementary Visit

Management Representative: Address (email):

Signature

S. Name Capacity/ Designation Opening Closing

N

Page 26: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 26 of 32

NML-GLP-F-2

Government of Nepal Ministry of health & population

Department of Drug Administration

National Medicines Laboratory

ASSESSOR’S OBSERVATIONS

Industry/Laboratory: Location:

Date: Section: Audit Criteria:

Auditee:

S. Cl No OBSERVATION REMARKS

N

Name of Assessor:

Signature

Page 27: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 27 of 32

NML-GLP-F-3 Government of Nepal

Ministry of health & population

Department of Drug Administration National Medicines Laboratory

TESTING/RE-TESTING WITNESSED DURING ASSESSMENT

Industry/Laboratory: Section: Location:

Discipline of Testing: Date(s)of Assessment

Test 1 Test 2 Test 3

Product / Material of Test

Test Witnessed

Test Method Specification

used

Range/Accuracy/Measurement

Uncertainty

1. Re-testing of Retained Sample

Sample ID

Date of Earlier Testing

Earlier Tested by

Earlier Reported Results

Results of Test Witnessed

Test conducted by

2. Testing of RM/CRM

Reference Material

Specified Value

Results of Test Witnessed

Remarks:

Deviations observed, if any

Conclusion on the technical

competence of the lab for the

test witnessed

(Enclose all supporting data sheets for tests witnessed)

(Signature & Name of Assessor)

Page 28: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 28 of 32

NML-GLP-F- 4 Government of Nepal

Ministry of health & population

Department of Drug Administration National Medicines Laboratory

CORRECTIVE ACTION ON NON-CONFORMITY

(Please use separate sheet for raising each Non-Conformity)

Industry/Laboratory: Location:

Date: Section: Activity Assessed:

NC No: Reference to Serial No. in Assessor Observation Sheet:

NON-CONFORMITY RAISED:

Ref to NML-GLP, Clause No: Type of NC: MAJOR / MINOR

Signature & Name of Laboratory Representative Signature & Name of Assessor

CORRECTIVE ACTION PROPOSED BY THE LABORATORY:

Signature of Laboratory Representative

ASSESSOR’S COMMENTS ON CORRECTIVE ACTION PROPOSED BY THE LABORATORY:

Signature of Assessor

REMARKS BY LEAD ASSESSOR, IF

ANY:

Signature & Name of Lead Assessor

Page 29: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 29 of 32

NML-GLP-F-5

Government of Nepal Ministry of health & population

Department of Drug Administration

National Medicines Laboratory

CONSOLIDATED NON-CONFORMITIES

Industry/Laboratory Location:

Date(s) of Visit: Section:

Audit Criteria:

NML- NML-GLP Check List Requirement No. of Non-Conformity raised during

GLP Assessment

Check List

Clause

No.

MAJOR MINOR

4 Management & Infrastructure

4.1 Organization and Management

4.2 Quality Management System

4.3 Control of documentation

4.4 Records

4.5 Data-processing equipment

4.6 Personnel

4.7 Premises

4.8 Equipment, instruments and other

devices

4.9 Contracts

5 Materials, equipment, instruments and other devices

5.1 Reagents

5.2 Reference substances and reference

materials

5.3 Calibration, verification of performance

and qualification of equipment,

instruments and other devices

5.4 Traceability

6 Working procedures

6.1 Incoming samples

6.2 Analytical worksheet

6.3 Validation of analytical procedures

Page 31 of 34

Page 30: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 30 of 32

6.4 Testing

6.5 Evaluation of test results

6.6 Certificate of analysis

6.7 Retained samples

7 Safety

7.1 General rules The non-conformities raised during the assessment are as a result of limited sampling and therefore it shall not be assumed that other non-conformities do not exist.

Signature & Name of Authorised representative of Signature & Name of Lead Assessor

Laboratory

Page 31: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 31 of 32

NML-GLP-F-6 Government of Nepal

Ministry of health & population

Department of Drug Administration

National Medicines Laboratory

SUMMARY OF THE ASSESSMENT

Industry/Laboratory: Location:

Laboratory Representative: Date(s) of Visit:

Type of Visit: Assessment / 1st

Surveillance / Re-Assessment / Supplementary Visit

Lead Assessor: Assessor 1: Assessor 2:

Date of earlier visit: Non-Conformities during earlier visit have/ have not been discharged.

ASSESSMENT SUMMARY:

Assessment Team Comment on compliance of laboratory to:

(a) Documentation:

(b) Equipment Status & Adequacy:

(c) Equipment Calibration and Traceability :

(d) Personnel Adequacy and Competency:

(e) Safety:

Non-Conformities raised during the MAJOR MINOR

assessment

COMMENTS OF ASSESSMENT TEAM:

Enclosures NML-GLP-F-1 NML-GLP-F-2 NML-GLP-F-3 NML-GLP-F-4 NML-GLP-F-5

Any other Supporting documents

No. of Pages

Page 32: National Guideline for Good Practices Fornml.gov.np/storage/resources/downloads/2019/Dec/22/1576990618… · WHO good practices for pharmaceutical quality control laboratories (WHO

Page 32 of 32

Acknowledgement by Authorised Representative of Signature of Lead Assessor & Date

Laboratory & Date